Clascoterone for Hair Loss: How the New Active Ingredient Could Revolutionize Treatment

Treatment for hereditary hair loss (androgenetic alopecia) could be on the verge of a historic breakthrough. After decades without fundamentally new drug approvals in this area, the pharmaceutical company Cosmo Pharmaceuticals released the highly anticipated Phase III results for its active ingredient Clascoterone on April 15, 2026. The data suggest that we may soon see the first topical antiandrogen on the market that directly targets the hair root and can significantly slow the progression of hair loss.

What is Clascoterone and how does it work?

Clascoterone (also known by its development name Breezula) is a topical androgen receptor antagonist. Unlike systemic drugs like finasteride, which affect hormone levels throughout the body, Clascoterone is applied locally as a 5% solution to the scalp. There, it blocks androgen receptors in the hair follicles so that the hormone responsible for hair loss, dihydrotestosterone (DHT), can no longer bind. In this way, the harmful effect of DHT on the hair roots is neutralized without lowering systemic testosterone levels.

Studies have shown that Clascoterone reduces the secretion of the pro-inflammatory and hair growth-inhibiting cytokine interleukin-6 (IL-6) in bald scalp areas. At the same time, it promotes the inductivity of dermal papillae and the proliferation of hair matrix keratinocytes to a similar extent as established active ingredients, leading to a visible thickening of the hair.

The groundbreaking Phase III results of 2026

The recently published data are based on the largest Phase III study program ever conducted for a topical treatment of androgenetic alopecia in men. The SCALP 1 and SCALP 2 studies involved a total of 1,465 patients at 51 centers in the USA and Europe. The results after 12 months are extremely promising.

Patients who used Clascoterone for the full 12 months experienced a statistically significant 2.39-fold improvement in hair density (Target Area Hair Count) compared to those who switched to a placebo after six months. Additionally, users reported 24.5% higher satisfaction with the treatment. The company now plans to apply for approval from the US FDA and the European Medicines Agency in early 2027. If approved, Clascoterone would be the first new medication against hair loss since finasteride was approved in 1997.

Holistic care: How you can support the effect

While we await the approval of new medical active ingredients, it is crucial to support the scalp and hair follicles as best as possible. A healthy microbiome and optimal nutrient supply form the foundation for any successful hair growth. A combination of internal and external care has proven particularly effective.

From the inside, you can strengthen your hair roots with targeted nutrients. The KÖ-HAIR Hair Loading Capsules offer an optimally balanced blend of vitamins, trace elements, and plant extracts that act as natural DHT blockers and support hair growth.

The Hair Loading Capsules supply the hair roots from within with essential nutrients.

Local stimulation of the scalp

For external use, experts recommend using circulation-promoting and cell-stimulating serums. The KÖ-HAIR Circulation Serum Spray uses the patented active ingredient Redensyl® to reactivate the stem cells of the hair follicles. Similar to future topical treatments, it is applied directly to the affected areas and specifically promotes microcirculation and cell growth there.

The Circulation Serum Spray revitalizes the scalp and promotes natural hair growth.

Creating the right foundation

Every topical treatment—whether current serums or future medications—can only work optimally if the scalp is clean and receptive. A deep-cleansing but gentle shampoo is therefore essential. The KÖ-HAIR Circulation Shampoo frees the pores from sebum and residues and ideally prepares the scalp for subsequent care. For users who have already undergone or are preparing for a hair transplant, the KÖ-HAIR care series offers a gentle and effective solution to maintain scalp health in the long term.

The Circulation Shampoo optimally prepares the scalp for active ingredient absorption.

Conclusion: A promising future

The positive results of the Clascoterone studies give millions of men worldwide new hope in the fight against hereditary hair loss. A locally acting androgen receptor blocker could revolutionize treatment options and offer an effective alternative or complement to existing therapies. Until the anticipated market launch, the combination of nutrient-rich nutrition, circulation-promoting serums, and optimal scalp hygiene remains the best strategy to keep your hair as long and healthy as possible.